Crawford Bayley
Crawford Bayley, Luthra & Luthra and Baker & McKenzie and Stephenson Harwood have advised on the $3.7bn takeover of Piramal Healthcare by US pharma major Abbott Laboratories.
Delhi start-up Axon Partners has landed a role next to Crawford Bayley and Linklaters on Jaiprakash Power Venture's surprise $200m (Rs 920 crore) convertible bond issue.
Crawford Bayley has picked up the latest Government disinvestment mandate for India's single largest iron ore producer and exporter National Mineral Development Corporation (NMDC), following Amarchand Mangaldas, Fox Mandal Little and Luthra & Luthra bagging the three other disinvestments of the past four months.
Crawford Bayley and Khaitan & Co have advised on the $400m (Rs 1,900 crore) takeover of listed Chennai pharmaceutical company Orchid Chemical & Pharmaceutical by US pharma major Hospira.
Legally India research has revealed Amarchand Mangaldas as the top IPO dealmaker of this financial year so far, while Khaitan & Co and Luthra & Luthra are in close contest for the runner-up spot. International and domestic firms are competing in a tightly bunched mid-field of the ranking.
Amarchand Mangaldas has acted on 70 per cent of qualified institutional placements (QIPs) in the first half of this financial year, with international firms, AZB & Partners, J Sagar Associates (JSA), Luthra & Luthra, S & R Associates and Crawford Bayley mopping up the rest.
Amarchand Mangaldas, AZB & Partners and Luthra & Luthra have benefited the most from the dash to hit the markets by month-end, as 16 companies filed draft initial public offering (IPO) prospectuses in the last two weeks.
Desai & Diwanji has poached a team of four lawyers from Crawford Bayley, taking on one senior associate as a partner.